Chemistry:Idarucizumab
From HandWiki
Short description: Medication
| Monoclonal antibody | |
|---|---|
| Type | Fab fragment |
| Source | Humanized (from mouse) |
| Target | Dabigatran |
| Clinical data | |
| Trade names | Praxbind |
| Other names | BI-655075 |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C2131H3299N555O671S11 |
| Molar mass | 47782.71 g·mol−1 |
Idarucizumab, sold under the brand name Praxbind, is a monoclonal antibody used as a reversal agent for dabigatran.[3]
Idarucizumab was developed by Boehringer Ingelheim. One study sponsored by the manufacturer found that idarucizumab effectively reversed anticoagulation caused by dabigatran within minutes.[5]
It was approved for medical use in the United States and in the European Union in 2015.[6][3][4]
Society and culture
Names
Idarucizumab is the International nonproprietary name (INN).[7] The description was updated in 2016.[8] Idarucizumab is the United States Adopted Name (USAN).[9]
See also
References
- ↑ "Prescription medicines: registration of new chemical entities in Australia, 2016". 21 June 2022. https://www.tga.gov.au/prescription-medicines-registration-new-chemical-entities-australia-2016.
- ↑ "Praxbind 2.5 g/50 mL solution for injection/infusion - Summary of Product Characteristics (SmPC)". 1 July 2022. https://www.medicines.org.uk/emc/product/5073.
- ↑ 3.0 3.1 3.2 "Praxbind- idarucizumab injection". 1 December 2019. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7400f8a-dcf4-a6df-6d07-983081b1bf34.
- ↑ 4.0 4.1 "Praxbind EPAR". 17 September 2018. https://www.ema.europa.eu/en/medicines/human/EPAR/praxbind.
- ↑ "Idarucizumab for Dabigatran Reversal". The New England Journal of Medicine 373 (6): 511–20. August 2015. doi:10.1056/NEJMoa1502000. PMID 26095746.
- ↑ "FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa". U.S. Food and Drug Administration (FDA) (Press release). Archived from the original on 2015-10-17. Retrieved 2015-10-17.
- ↑ "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 71". WHO Drug Information 28 (1): 90–91. 2014.
- ↑ "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 76". WHO Drug Information 30 (3): 544. 2016.
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Idarucizumab , American Medical Association.
External links
- "Idarucizumab". Drug Information Portal. U.S. National Library of Medicine. https://druginfo.nlm.nih.gov/drugportal/name/idarucizumab.
 |  |
